Orphan Europe Report issue

For profit Phase 2
Founded: Paris France (1990)
Status: Acquired by Recordati (2007)

Organization Overview

First Clinical Trial
2007
NCT00283387
First Marketed Drug
1996
betaine
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ORPHAN EUROPE

Active Ingredients

Marketed Drugs (2)

betaine (1996)

carglumic acid (carbaglu) (2010)

Drugs in Phase 2 Trials (1)

betaine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperoxaluria, Primary (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1